Answers are grounded in this paper and cite their sources.
Regulatory agencies face challenges in reviewing data from global clinical trials (GCTs) in the era of globalization of drug development. One major challenge is consideration of ethnic factors in evaluating GCT data so as to extrapolate foreign population data to one's own national population. Here, we present the Pharmaceuticals and Medical Devices Agency (PMDA) perspective in reviewing GCT data in new drug applications (NDAs) and discuss future challenges for new drug approval.
No takes yet. Share an insight, caveat, or question.
Asano et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: